GlassScriptPhysician profile
John T Griffin
NPI 1053399873
$605.88
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $107 · 2020: $243 · 2021: $256.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $163.69 | 2019-2021 | |
| Taiho Oncology, INC. | $69.80 | 2021 | |
| Novartis Pharmaceuticals Corporation | $62.64 | 2019-2021 | |
| Pfizer INC. | $55.59 | 2021 | |
| Merck Sharp & Dohme LLC | $39.44 | 2020-2021 | |
| Abbvie INC. | $21.70 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.48 | 2021 | |
| Novo Nordisk INC | $19.63 | 2020 | |
| Eisai INC. | $19.19 | 2020 | |
| Abbott Laboratories | $18.38 | 2021 | |
| Esperion Therapeutics, INC. | $17.44 | 2020 | |
| Supernus Pharmaceuticals, INC. | $17.28 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.80 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.44 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.16 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $15.79 | 2019 | |
| Lilly USA, LLC | $15.43 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Griffin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.